Article
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
Lung cancer (Amsterdam, Netherlands) - 1 Oct 2024
Waterhouse David M, Rothschild Sacha, Dooms Christophe, Mennecier Bertrand, Bozorgmehr Farastuk, Majem Margarita, van den Heuvel Michel H, Linardou Helena, Chul Cho Byoung, Roberts-Thomson Rachel, Tanaka Kentaro, Blais Normand, Schvartsman Gustavo, Holmskov Hansen Karin, Chmielewska Izabela, Forster Martin D, Giannopoulou Christina, Stollenwerk Björn, Obiozor Cynthia C, Wang Yang, Novello Silvia
Abstract excerpt
BACKGROUND: In the CodeBreaK 200 phase III, open-label trial, sotorasib significantly improved efficacy versus docetaxel in previously treated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). Patient-reported outcomes (PROs) for global health status, physical functioning, dyspnea, and cough favored sotorasib over docetaxel. Here, we report sotorasib's additional impact on quality of life (QOL)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.